

COVID-19 Vaccine Quick Reference

8 weeks = 56 days
 3 months = 84 days
 6 months = 168 days

Table-1: Recommended Schedule (excluding severely or moderately immunocompromised)

	Vaccine	Primary Series	Boosters
Ages 6 mths through 4 years 5 th birthday and onward to receive Pfizer pediatric Complete series with the same product	Moderna Pediatric formulation (royal blue cap)	2 dose series 8 weeks apart (minimum 28 days with informed consent) Dosage: 0.25 ml (25 mcg)	No
	Pfizer pediatric formulation (maroon cap)	3 dose series 2nd dose, 8 weeks after 1 st dose (minimum 21 days with informed consent) 3rd dose, 8 weeks after 2 nd dose (no other minimum interval) Dosage: 0.2 ml (3 mcg)	No
Ages 5 to 11 Must be 5 yrs on day of vaccination *Preferentially to receive Pfizer over Moderna	Pfizer pediatric formulation (orange cap)	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.2 ml (10 mcg)	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.2 ml (10 mcg)
Ages 12 to 17 *Preferentially to receive Pfizer over Moderna	Pfizer Adult/Adolescent formulation (purple cap)	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.3 ml (30 mcg)	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
Ages 18 + <ul style="list-style-type: none"> 18 to 29 to receive Pfizer for primary series (Moderna if requested with informed consent) 30+ can receive Pfizer or Moderna for primary series 18+ recommended Bivalent for boosters. Only receive monovalent if requested 70+ and congregate residents care settings: if requesting monovalent Moderna for booster should be 100 mcg dose 	Pfizer Adult/Adolescent formulation (purple vial)	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.3 ml (30 mcg)	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
	Moderna Monovalent	2 dose series 8 weeks apart (minimum 28 days with informed consent) Dosage: 0.5 ml (100 mcg)	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.25ml (50 mcg) for under 70 0.5 ml (100 mcg) for 70+ & congregate
	Moderna Bivalent	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5ml (50 mcg)
	Novavax	2 dose series 8 weeks apart (minimum 21 days with informed consent) Dosage: 0.5ml	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5ml
	*For those who can't/won't receive mRNA vaccines	8 weeks apart (minimum 21 days with informed consent) Dosage: 0.5ml	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5ml

Table 2: Those who are Severely or Moderately Immunocompromised which includes:

- Receiving dialysis (hemodialysis or peritoneal dialysis)
- Receiving active treatment (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Individuals with HIV with prior AIDS defining illness or prior CD4 count $\leq 200/\text{mm}^3$ or prior CD4 fraction $\leq 15\%$ or (in children 5-11 years) perinatally acquired HIV infection
- Individuals receiving active treatment with the specific immunosuppressive therapies (refer to list in directive)

Ages 6 mths through 4 yrs	Vaccine	Primary Series	Boosters
5 th birthday and onward to receive Pfizer pediatric Awaiting NACI on Pfizer under 5 immunocompromised	Moderna Pediatric formulation (royal blue cap)	3 dose series 8 weeks between doses (minimum 28 days with informed consent) Dosage: 0.25 ml (25 mcg)	No
Ages 5 to 11 *Preferentially to receive Pfizer over Moderna	Pfizer pediatric formulation (orange cap)	3 dose series 8 week between doses (minimum 21 days with informed consent) Dosage: 0.2 ml (10 mcg)	Yes 6 monthshs after last dose (minimum 3 months with informed consent) Dosage: 0.2 ml (10 mcg)
Ages 12 to 17 *Preferentially to receive Pfizer over Moderna for primary series Moderna bivalent is recommended booster product.	Pfizer Adult/Adolescent formulation (purple cap)	3 dose series 8 weeks between doses (minimum 21 days with informed consent) Dosage: 0.3 ml (30 mcg)	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
	Moderna Bivalent	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5ml (50 mcg)
Ages 18 + <ul style="list-style-type: none"> • 18 to 29 to receive Pfizer for primary series (Moderna if requested with informed consent) • 18+ recommended Bivalent for boosters. Only receive monovalent if requested 	Pfizer Adult/Adolescent formulation (purple cap)	3 dose series 8 weeks between doses (minimum 21 days with informed consent) Dosage: 0.3 ml (30 mcg)	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.3 ml (30 mcg)
	Moderna Monovalent (red cap) **only to be used when requested with informed consent	3 dose series 8 weeks between doses (minimum 28 days with informed consent) Dosage: 0.5 ml (100 mcg)	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5 ml (100 mcg)
	Moderna Bivalent	N/A See above for primary series recommendations	6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5ml (50 mcg)
	Novavax	3 dose series 8 weeks between doses (minimum 21 days with informed consent) Dosage: 0.5 ml	Yes 6 months after last dose (minimum 3 months with informed consent) Dosage: 0.5 ml

Severely or Moderately Immunocompromised: Re-immunization Recommendation

Those who have received a hematopoietic stem cell transplants (HSCT), hematopoietic cell transplants (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy should be re-vaccinated with a new COVID-19 vaccine primary series post-transplantation due to the loss of immunity following therapy or transplant. For additional information, please refer to the updated [COVID-19 Vaccination Recommendations for Special Populations](#) document.

Post Infection Immunization Guidance

Infection timing relative to COVID-19 vaccination	Population	Suggested interval between infection* and vaccination
Infection prior to completion or initiation of primary vaccination series	Individuals 6 months of age and older who are not considered moderately to severely immunocompromised and with no previous history of multisystem inflammatory syndrome in children (MIS-C)	Receive the vaccine 2 months (56 days) after symptom onset or positive test (if asymptomatic)
	Individuals 6 months of age and older who are moderately to severely immunocompromised and with no previous history of MIS-C	Receive the vaccine dose 1 to 2 months (28 to 56 days) after symptom onset or positive test (if asymptomatic)
	Individuals 6 months of age and older with a previous history of MIS-C (regardless of immunocompromised status)	Receive the vaccine dose when clinical recovery has been achieved or ≥ 90 days since the onset of MIS-C, whichever is longer
Infection after primary series	Individuals currently eligible for booster dose(s)	A minimum of 3 months (84 days) after symptom onset or positive test (if asymptomatic); however, a 6 month (168 day) interval may provide better immune response regardless of the product given.

*A previous infection with SARS-CoV-2 is defined as:

- Confirmed by a molecular (e.g., PCR) or rapid antigen test; or
- Symptomatic **AND** a household contact of a confirmed COVID-19 case.